$2.23
13.20% yesterday
Nasdaq, Aug 12, 10:15 pm CET
ISIN
US4622601007
Symbol
IOVA

Iovance Biotherapeutics Inc Stock price

$2.23
+0.22 10.95% 1M
-3.11 58.24% 6M
-5.17 69.86% YTD
-7.86 77.89% 1Y
-10.43 82.39% 3Y
-26.03 92.11% 5Y
-5.01 69.20% 10Y
-2.98 57.18% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.26 13.20%
ISIN
US4622601007
Symbol
IOVA
Industry

Key metrics

Basic
Market capitalization
$712.9m
Enterprise Value
$354.1m
Net debt
positive
Cash
$359.7m
Shares outstanding
333.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.4 | 2.3
EV/Sales
1.7 | 1.2
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
78.0%
Return on Equity
-52.4%
ROCE
-47.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$212.7m | $306.2m
EBITDA
$-351.7m | $-358.4m
EBIT
$-398.8m | $-377.5m
Net Income
$-375.4m | $-385.8m
Free Cash Flow
$-347.5m
Growth (TTM | estimate)
Revenue
11,035.1% | 86.6%
EBITDA
20.3% | -4.1%
EBIT
14.7% | 2.7%
Net Income
16.5% | -3.7%
Free Cash Flow
14.2%
Margin (TTM | estimate)
Gross
21.7%
EBITDA
-165.4% | -117.1%
EBIT
-187.5%
Net
-176.5% | -126.0%
Free Cash Flow
-163.4%
More
EPS
$-1.2
FCF per Share
$-1.0
Short interest
32.4%
Employees
838
Rev per Employee
$200.0k
Show more

Is Iovance Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Iovance Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Iovance Biotherapeutics Inc forecast:

12x Buy
67%
5x Hold
28%
1x Sell
6%

Analyst Opinions

18 Analysts have issued a Iovance Biotherapeutics Inc forecast:

Buy
67%
Hold
28%
Sell
6%

Financial data from Iovance Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
213 213
11,035% 11,035%
100%
- Direct Costs 166 166
824% 824%
78%
46 46
387% 387%
22%
- Selling and Administrative Expenses 163 163
48% 48%
77%
- Research and Development Expense 274 274
20% 20%
129%
-352 -352
20% 20%
-165%
- Depreciation and Amortization 47 47
79% 79%
22%
EBIT (Operating Income) EBIT -399 -399
15% 15%
-188%
Net Profit -375 -375
17% 17%
-176%

In millions USD.

Don't miss a Thing! We will send you all news about Iovance Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Iovance Biotherapeutics Inc Stock News

Positive
The Motley Fool
4 days ago
Experienced investors understand that being in the stock market requires a long-term, multiyear mindset. For truly patient people though, the reward is well worth the wait; you'd be hard-pressed to find better returns on your money than the market's average annual gain of about 10%.
Negative
The Motley Fool
4 days ago
Investors are typically quite harsh on publicly traded companies that don't make their quarterly estimates, a dynamic vividly on display Friday with biotech stock Iovance Biotherapeutics (IOVA -20.08%). The company published its second-quarter earnings after market close the previous day, and the market reacted by trading the stock down by more than 20%.
Neutral
Seeking Alpha
5 days ago
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Daniel G. Kirby - Chief Commercial Officer Frederick G.
More Iovance Biotherapeutics Inc News

Company Profile

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Head office United States
CEO Frederick Vogt
Employees 838
Founded 2007
Website www.iovance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today